Lord's Mark Industries Limited has entered into a landmark Technology Transfer Agreement with C-MET to develop and commercialize the world’s first AI-powered, radiation-free wearable device for early breast cancer detection. The innovation promises safer, non-invasive diagnostics with global commercialization expected by year-end.
Lord's Mark Industries announced a breakthrough collaboration with the Centre for Materials for Electronic Technology (C-MET), under MeitY, to pioneer an indigenous MedTech solution for breast cancer screening. This wearable device integrates advanced thermal sensors with AI-driven mapping to detect abnormalities without radiation exposure.
Technology Innovation
The device leverages high-precision thermal sensors and artificial intelligence to identify early-stage abnormalities. Unlike mammography, it is painless, portable, and eliminates radiation risks, making screening more accessible.
Market Potential
With the global breast cancer diagnostics market projected to reach USD 12.88 billion by 2035, this partnership positions Lord’s Mark Industries at the forefront of preventive healthcare innovation.
Key Highlights
-
Objective: Manufacture and commercialize AI-powered, radiation-free breast screening wearable
-
Technology: Thermal sensors with AI-driven temperature mapping
-
Market Potential: USD 12.88 billion by 2035
-
Strategic Impact: Affordable, portable, scalable solution leveraging C-MET’s R&D and Lord’s Mark’s manufacturing strength
Management Insight
Managing Director Sachidanand Upadhyay emphasized that the collaboration represents a defining step in building globally competitive, indigenous healthcare technologies that are non-invasive, AI-driven, and accessible.
Sources: Lord’s Mark Industries Limited disclosure to BSE